VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

January 14, 2019

Study Completion Date

January 14, 2019

Conditions
Invasive AspergillosisInvasive Pulmonary Aspergillosis
Interventions
DRUG

Investigational Agent: VL-2397

VL-2397

DRUG

Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B

Voriconazole, Isavuconazole, or Liposomal amphotericin B

Trial Locations (28)

1000

Jules Bordet Institute, Department of Infectious Disease, Brussels

3000

University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven

8000

General Hospital Saint-Jan, Department of Hematology, Bruges

19718

Christiana Care Health Services, Department of Medicine, Newark

30912

Medical College of Georgia at Augusta University, Augusta

35233

University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham

38700

Grenoble University Hospital Center, Department of Hematology, Grenoble

48201

DMC Harper University Hospital, Detroit

53226

Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Department of Medicine, Minneapolis

63110

Washington University School of Medicine, Division of Infectious Disease, St Louis

67200

Hautepierre Hospital, Strasbourg

69310

South Lyon Hospital Center, Pierre-Bénite

77030

The University of Texas Health Science Center, Department of Internal Medicine, Houston

81737

Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology, Munich

92093

UC San Diego Moores Cancer Center, La Jolla

95817

UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento

98109

Fred Hutchinson Cancer Research Center (FHCRC), Seattle

B-2650

University Hospital Antwerp (UZA), Department of Hematology, Edegem

B-5530

UCL Mont-Godinne University Hospitals, Department of Hematology, Yvoir

L8V 1C3

Hamilton Health Sciences, Infectious Disease Research, Hamilton

M5G 2N2

Toronto General Hospital, Toronto

H4A 3J1

McGill University Health Centre (MUHC), Division of Infectios Diseases, Montreal

07740

University Hospital Jena, Jena

519-809

Chonnam National University, Hwasun

06351

Samsung Medical Center, Seoul

11 0-744

Seoul National University Hospital, Seoul

138-736

Asan Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Vical

INDUSTRY

NCT03327727 - VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults | Biotech Hunter | Biotech Hunter